AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

Acorda Therapeutics Inc

Healthcare US ACOR


Last update at 2024-05-08T13:30:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -35.24700M -109.07400M -107.66700M -274.24700M 20.42M
Minority interest - - - - 0.00000M
Net income -65.91600M -103.95400M -99.59400M -272.96500M 33.68M
Selling general administrative 106.26M 124.40M 152.58M 192.85M 172.25M
Selling and marketing expenses - - - - -
Gross profit 88.23M 88.28M 119.45M 157.56M 372.12M
Reconciled depreciation 32.81M 30.76M 41.30M 34.57M 11.48M
Ebit -42.03600M -77.29900M -86.89700M 14.55M 137.01M
Ebitda -10.03000M -44.79600M -64.95500M 40.18M 148.49M
Depreciation and amortization 32.01M 32.50M 21.94M 25.64M 11.48M
Non operating income net other - - 56.08M 59.26M 3.53M
Operating income -42.03600M -77.29900M -86.89700M 14.55M 38.49M
Other operating expenses 160.60M 206.37M 239.86M 313.41M 377.95M
Interest expense 28.29M 30.04M 30.57M 21.87M 21.60M
Tax provision 30.67M -5.12000M -8.07300M -1.28200M -13.25900M
Interest income 1.91M 0.00500M 0.82M 4.17M 3.52M
Net interest income -28.29100M -30.03000M -29.75800M -17.70200M -18.07900M
Extraordinary items - - - - 14.80M
Non recurring - - 4.13M 277.56M -
Other items - - - - -
Income tax expense 30.67M -5.12000M -8.07300M -1.28200M -13.25900M
Total revenue 118.57M 129.07M 152.97M 192.41M 471.43M
Total operating expenses 130.27M 165.58M 206.35M 278.56M 278.64M
Cost of revenue 30.33M 40.79M 33.51M 34.85M 99.31M
Total other income expense net 6.79M -31.77500M -20.77000M -288.79500M -73.06300M
Discontinued operations - - - - -
Net income from continuing ops -65.91600M -103.95400M -99.59400M -272.96600M 33.68M
Net income applicable to common shares -65.91600M -103.95400M -99.59400M -272.96600M 33.68M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 395.60M 455.47M 632.68M 799.72M 1299.67M
Intangible assets 305.09M 335.98M 366.98M 402.33M 428.57M
Earning assets - - - - -
Other current assets 11.08M 7.57M 16.38M 15.13M 30.11M
Total liab 301.97M 304.33M 394.73M 488.90M 687.68M
Total stockholder equity 93.62M 151.14M 237.96M 310.82M 611.98M
Deferred long term liab - - 20.31M 68.99M 7.48M
Other current liab 25.93M 6.39M 10.36M 12.70M 13.90M
Common stock 0.02M 0.01M 0.00900M 0.05M 0.05M
Capital stock 0.02M 0.01M 0.00900M 0.05M 0.05M
Retained earnings -936.27300M -870.35700M -766.40300M -666.80900M -393.84300M
Other liab 92.65M 67.55M 74.10M 161.25M 204.29M
Good will - - - 0.00000M 282.06M
Other assets 0.50M 27.17M 37.10M 30.30M 0.41M
Cash 37.54M 45.63M 71.37M 62.09M 293.56M
Cash and equivalents - - - - -
Total current liabilities 37.95M 54.02M 137.25M 86.39M 140.26M
Current deferred revenue 0.38M 27.64M - - -
Net debt 135.38M 145.31M 188.58M 187.53M 50.19M
Short term debt 1.54M 8.19M 76.58M 8.35M 0.62M
Short long term debt - - 68.63M 3.81M 19.00M
Short long term debt total 172.92M 190.94M 259.95M 249.61M 343.76M
Other stockholder equity 1029.24M 1022.50M 1007.15M 978.75M 1002.97M
Property plant equipment 7.89M 11.13M 25.74M 142.53M 60.52M
Total current assets 82.11M 102.16M 221.34M 201.11M 528.11M
Long term investments - - - - -
Net tangible assets -211.46500M -184.84300M -129.02600M -54.94800M -76.91500M
Short term investments - - 0.00000M 63.75M 151.99M
Net receivables 13.87M 17.00M 20.19M 22.08M 23.43M
Long term debt 167.03M 178.67M 166.17M 218.27M 343.14M
Inventory 12.75M 18.55M 28.68M 25.22M 29.01M
Accounts payable 10.09M 11.81M 50.32M 65.33M 125.74M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.63M -1.01700M -2.80300M -1.16900M 2.81M
Additional paid in capital - - - - -
Common stock total equity - - 0.00900M 0.05M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - -766.40300M -666.80900M -393.84300M
Treasury stock - - -0.63800M -0.63800M -2.13300M
Accumulated amortization - - - - -
Non currrent assets other 0.50M 6.20M 18.62M 30.30M 0.41M
Deferred long term asset charges - - - - -
Non current assets total 313.48M 353.31M 411.35M 598.61M 771.56M
Capital lease obligations 5.89M 12.27M 25.14M 30.74M -
Long term debt total - - 166.17M 218.27M 343.14M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.13600M 73.78M 63.75M 89.92M -150.83400M
Change to liabilities -7.35900M 1.11M -8.97100M -60.99500M -3.43600M
Total cashflows from investing activities -0.13600M 73.78M 59.36M -0.50500M -176.86500M
Net borrowings - -69.65500M -0.59700M -60.48300M -0.65700M
Total cash from financing activities 0.00000M -69.65500M -1.66800M -60.55000M 12.80M
Change to operating activities 0.68M 12.78M -1.41700M 14.02M -15.31600M
Net income -65.91600M -103.95400M -99.59400M -272.96600M 33.68M
Change in cash -20.54800M -37.67200M -2.29600M -189.16000M -13.68700M
Begin period cash flow 65.22M 102.89M 105.19M 294.35M 308.04M
End period cash flow 44.67M 65.22M 102.89M 105.19M 294.35M
Total cash from operating activities -20.92400M -41.34800M -61.00600M -128.16700M 150.79M
Issuance of capital stock - - 0.00000M 0.02M 15.20M
Depreciation 32.81M 33.95M 41.30M 34.57M 11.48M
Other cashflows from investing activities - - - 89.92M 7.30M
Dividends paid - - - - -63.92800M
Change to inventory 5.80M 7.86M -3.45600M 3.79M 8.44M
Change to account receivables 2.58M 3.19M 1.89M 1.35M 57.97M
Sale purchase of stock - - 0.00000M -0.09100M -1.74400M
Other cashflows from financing activities -0.13600M 73.78M -1.07100M -4.67000M 63.93M
Change to netincome -6.43800M -12.55800M -7.17800M 234.76M -1.09000M
Capital expenditures 0.14M 0.19M 4.39M 90.43M 33.91M
Change receivables - - 1.89M 1.35M 57.97M
Cash flows other operating - - 14.30M -82.75600M 29.34M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -3.31400M -189.22200M -13.27500M
Change in working capital 1.70M 24.93M -11.95400M -41.40500M 47.61M
Stock based compensation 1.49M 3.00M 8.10M 14.25M 21.25M
Other non cash items -21.67700M 5.91M -3.52300M 139.36M 51.28M
Free cash flow -21.06000M -41.53900M -65.39600M -218.59300M 116.88M


  • Previous Close -
  • Market Cap17.59M
  • Volume1577
  • P/E Ratio5.43
  • Dividend Yield1.86%
  • EBITDA11.51M
  • Revenue TTM111.12M
  • Revenue Per Share TTM87.94
  • Gross Profit TTM 82.43M
  • Diluted EPS TTM2.61

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Acorda Therapeutics Inc
0.78 -% 0.78 5.43 - 0.18 0.34 1.56 3.93
Zoetis Inc
0.68 0.39% 173.96 40.18 30.96 10.67 17.60 11.27 26.18
Merck KGaA ADR
0.51 1.41% 36.61 21.25 14.93 3.10 2.14 3.60 12.98
MERCK Kommanditgesellschaft auf Aktien
6.91 3.93% 182.50 21.73 14.95 3.16 2.15 3.56 12.82
Takeda Pharmaceutical Co Ltd ADR
-0.045 0.34% 13.35 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News


Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Acorda Therapeutics Inc

420 Saw Mill River Road, Ardsley, NY, United States, 10502

Key Executives

Name Title Year Born
Dr. Ron Cohen M.D. Founder, CEO, Pres & Director 1956
Dr. Burkhard Blank M.D. Interim Head of Drug Safety 1955
Mr. Michael A. Gesser M.B.A. Chief Financial Officer 1963
Mr. Robert Morales Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller 1968
Ms. Felicia Vonella VP of Investor Relations NA
Mr. Neil S. Belloff Esq. Gen. Counsel & Corp. Sec. 1960
Ms. Tierney Saccavino Exec. VP of Corp. Communications NA
Ms. Denise J. Duca Exec. VP of HR NA
Mr. Andrew Mayer J.D. Sr. VP NA
Mr. Kerry M. Clem Chief Commercial Officer 1970

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).